⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17818284 | 0.90 | — | — | |
| SCHEMBL1466357 | 0.80 | — | — | |
| SCHEMBL5360866 | 0.76 | — | — | |
| SCHEMBL234746 | 0.72 | — | — | |
| SCHEMBL17818303 | 0.71 | — | — | |
| SCHEMBL2717494 | 0.70 | GRM5 (0.39) | — | |
| SCHEMBL767264 | 0.70 | CYP1A2 (0.35) | — | |
| SCHEMBL3852652 | 0.69 | — | — | |
| SCHEMBL5916128 | 0.69 | — | — | |
| SCHEMBL5193501 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107001295-B | Isoxazole hydroxamic acid compounds as LpxC inhibitors | 诺华股份有限公司 | 2021-02-02 | — | — | CN | disclosed |
| EP-3468957-B1 | CRYSTALLINE FORM OF (R)-4-(5-(CYCLOPROPYLETHYNYL)ISOXAZOL-3-YL)-N-HYDROXY-2-METHYL-2-(METHYLSULFONYL)BUTANAMIDE AS AN ANTIBACTERIAL AGENT | NOVARTIS AG (CH) | 2020-08-26 | — | — | EP | disclosed |
| EP-3233843-B1 | ISOXAZOLE HYDROXAMIC ACID COMPOUNDS AS LPXC INHIBITORS | NOVARTIS AG (CH) | 2019-10-16 | — | — | EP | disclosed |
| EP-3468957-A1 | CRYSTALLINE FORM OF (R)-4-(5-(CYCLOPROPYLETHYNYL)ISOXAZOL-3-YL)-N-HYDROXY-2-METHYL-2-(METHYLSULFONYL)BUTANAMIDE AS AN ANTIBACTERIAL AGENT | NOVARTIS AG (CH) | 2019-04-17 | — | — | EP | disclosed |
| US-10071973-B2 | Crystalline isoxazole hydroxamic acid compounds | NOVARTIS AG (CH) | 2018-09-11 | — | — | US | disclosed |
| US-10029994-B2 | Isoxazole hydroxamic acid compounds as LpxC inhibitors | NOVARTIS AG (CH) | 2018-07-24 | — | — | US | disclosed |
| US-20180030004-A1 | ISOXAZOLE HYDROXAMIC ACID COMPOUNDS AS LpxC INHIBITORS | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2018-02-01 | — | — | US | disclosed |
| WO-2017216705-A1 | CRYSTALLINE FORM OF (R)-4-(5-(CYCLOPROPYLETHYNYL)ISOXAZOL-3-YL)-N-HYDROXY-2-METHYL-2-(METHYLSULFONYL)BUTANAMIDE AS AN ANTIBACTERIAL AGENT | NOVARTIS AG (CH) | 2017-12-21 | — | — | WO | disclosed |
| US-20170355684-A1 | CRYSTALLINE ISOXAZOLE HYDROXAMIC ACID COMPOUNDS | NOVARTIS PHARMA AG (CH) | 2017-12-14 | — | — | US | disclosed |
| US-9815804-B2 | Isoxazole hydroxamic acid compounds as LpxC inhibitors | NOVARTIS AG (CH) | 2017-11-14 | — | — | US | disclosed |
| EP-3233843-A1 | ISOXAZOLE HYDROXAMIC ACID COMPOUNDS AS LPXC INHIBITORS | Novartis AG (CH) | 2017-10-25 | — | — | EP | disclosed |
| US-20170088525-A1 | ISOXAZOLE HYDROXAMIC ACID COMPOUNDS AS LpxC INHIBITORS | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2017-03-30 | — | — | US | disclosed |
| US-9549916-B2 | Isoxazole hydroxamic acid compounds as LpxC inhibitors | NOVARTIS AG (CH) | 2017-01-24 | — | — | US | disclosed |
| WO-2016097995-A1 | ISOXAZOLE HYDROXAMIC ACID COMPOUNDS AS LPXC INHIBITORS | NOVARTIS AG (CH) | 2016-06-23 | — | — | WO | disclosed |
| US-20160166548-A1 | ISOXAZOLE HYDROXAMIC ACID COMPOUNDS AS LpxC INHIBITORS | NOVARTIS AG (CH) | 2016-06-16 | — | — | US | disclosed |